Upcoming launches include two adalimumab and one trastuzumab that aspire to compete against 'Humira' and 'Herceptin'. Several enoxaparins, sultate chondroitins and a glargine would also be added to the arsenal.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
